García-Tornel Á, Flores A, Terceño M et al. Stroke. 2023 Mar;54(3):770-780. doi: 10.1161/STROKEAHA.122.041013. Epub 2023 Feb 27. PMID: 36848432
Publicaciones
Evaluation of Bioactive Effects of Five Plant Extracts with Different Phenolic Compositions against Different Therapeutic Targets
Villegas-Aguilar MDC, Sánchez-Marzo N, Fernández-Ochoa Á et al. Antioxidants (Basel). 2024 Feb 8;13(2):217. doi: 10.3390/antiox13020217. PMID: 38397815
Extracellular vesicles secreted by triple-negative breast cancer stem cells trigger premetastatic niche remodeling and metastatic growth in the lungs
González-Callejo P, Gener P, Díaz-Riascos ZV et al. Int J Cancer. 2023 May 15;152(10):2153-2165. doi: 10.1002/ijc.34447. Epub 2023 Feb PMID: 36705298
circRNA from APP Gene Changes in Alzheimer’s Disease Human Brain
Urdánoz-Casado A, Sánchez-Ruiz de Gordoa J et al. Int J Mol Sci. 2023 Feb 21;24(5):4308. doi: 10.3390/ijms24054308. PMID: 36901741
APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke
Hernández-Jiménez M, Abad-Santos F, Cotgreave I et al. Front Neurol. 2023 Feb 24;14:1127585. doi: 10.3389/fneur.2023.1127585. eCollection 2023. PMID: 36908619
Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
Meca-Lallana V, Esparcia-Pinedo L, Aguirre C et al. Clin Immunol Commun. 2023 Dec;3:6-13. doi: 10.1016/j.clicom.2023.02.001. Epub 2023 Feb 4. PMID: 38014396
European Stroke Organisation (ESO) Guidelines on Moyamoya angiopathy Endorsed by Vascular European Reference Network (VASCERN)
Bersano A, Khan N, Fuentes B et al. Eur Stroke J. 2023 Mar;8(1):55-84. doi: 10.1177/23969873221144089. Epub 2023 Feb 2. PMID: 37021176
Influence of Temperature Chronobiology on Stroke Outcome
Alonso-Alonso ML, Sampedro-Viana A, Rodríguez-Yáñez M et al. Int J Mol Sci. 2023 Feb 13;24(4):3746. doi: 10.3390/ijms24043746. PMID: 36835156
https://pubmed.ncbi.nlm.nih.gov/36835156/
Abstract: : The circadian system regulates numerous physiological variables, including body temperature. Additionally, a circadian patter has been described in stroke onset. Considering this, we hypothesised that the chronobiology of temperature may have an impact on stroke onset and functional outcomes. We also studied the variation of blood biomarkers according to stroke onset time. This is a retrospective observational study. Of the patients included, 2763 had a stroke between midnight and 8:00 h; 1571 between 8:00–14:00 h; and 655 between 14:00 h and midnight. Axillary temperature was measured at admission. At this time, blood samples were collected for biomarker analysis (TNF-α, IL-1β, IL-6, IL-10, and glutamate). Temperature was higher in patients admitted from 8:00 h to midnight (p < 0.0001). However, the percentage of poor outcome at 3 months was highest in patients from midnight to 8:00 h (57.7%, p < 0.001). The association between temperature and mortality was highest during night time (OR: 2.79; CI 95%: 2.36–3.28; p < 0.001). These patients exhibited high glutamate (220.2 ± 140.2 µM), IL-6 (32.8 ± 14.3 pg/mL) and low IL-10 (9.7 ± 14.3 pg/mL) levels. Therefore, temperature chronobiology could have a significant impact on stroke onset and functional outcome. Superficial body hyperthermia during sleep seems to be more dangerous than during wakefulness. Further studies will be necessary to confirm our data.
Funding: This research was funded by Spanish Ministry of Science and Innovation (SAF2017-84267- R), PDC2021-121455-I00, Xunta de Galicia (Consellería de Educación: IN607A2022-03), Instituto de Salud Carlos III (ISCIII) (PI17/00540, PI17/01103), ISCIII/PI21/01256/Co-financed by the European Union, Spanish Research Network on Cerebrovascular Diseases RETICS-INVICTUS PLUS (RD16/0019/0001), RICORS-ICTUS (Cerebrovascular diseases) D21/0006/0003. M. Bazarra-Barreiros is a PFIS Researcher (FI22/00200) of Instituto de Salud Carlos III. T. Sobrino (CPII17/00027), F. Campos (CPII19/00020) and R. Iglesias-Rey (CP22/00061) from the Miguel Servet Program of Instituto de Salud Carlos III and Co-financed by the EU. Sponsors did not participate in the study design, collection, analysis, or interpretation of the data, or in writing the report.
Direct Mechanical Thrombectomy vs. Bridging Therapy in Stroke Patients in A «Stroke Belt» Region of Southern Europe
J Pers Med. 2023 Feb 28;13(3):440. doi: 10.3390/jpm13030440. PMID: 36983622
https://pubmed.ncbi.nlm.nih.gov/36983622/
Abstract: The aim of this 4-year observational study is to analyze the outcomes of stroke patients treated with direct mechanical thrombectomy (dMT) compared to bridging therapy (BT) (intravenous thrombolysis [IVT] + BT) based on 3-month outcomes, in real clinical practice in the «Stroke Belt» of Southern Europe. In total, 300 patients were included (41.3% dMT and 58.6% BT). The frequency of direct referral to the stroke center was similar in the dMT and BT group, whereas the time from onset to groin was longer in the BT group (median 210 [IQR 160–303] vs. 399 [IQR 225–675], p = 0.001). Successful recanalization (TICI 2b-3) and hemorrhagic transformation were similar in both groups.
The BT group more frequently showed excellent outcomes at 3 months (32.4% vs. 15.4%, p = 0.004). Multivariate analysis showed that BT was independently associated with excellent outcomes (OR 2.7. 95% CI,1.2–5.9, p = 0.02) and lower mortality (OR 0.36. 95% CI 0.16–0.82, p = 015). Conclusions: Compared with dMT, BT was associated with excellent functional outcomes and lower 3-month mortality in this real-world clinical practice study conducted in a region belonging to the “Stroke Belt” of Southern Europe. Given the disparity of results on the benefit of BT in the current evidence, it is of vital importance to analyze the convenience of its use in each health area.
Funding: This study is part of the Spanish Health Outcomes-Oriented Cooperative Research Networks (RICORS-ICTUS), Instituto de Salud Carlos III (Carlos III Health Institute), Ministerio de Ciencia e Innovación (Ministry of Science and Innovation), RD21/0006/0010.